Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.

NCT Number	NCT05554302
Lead Sponsor	Baptist Health South Florida Collaborators: Blue Earth Diagnostics
Conditions	Brain Metastases, Brain Cancer
Enrollment	20 participants
Start Date	2023-01-10
Primary Completion	2030-01 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-01